Flap amputation with phototherapeutic keratectomy (PTK) and adjuvant mitomycin C for severe post-LASIK epithelial ingrowth

Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami University, Miami, FL 33136, USA.
European journal of ophthalmology (Impact Factor: 1.07). 01/2009; 19(2):301-3.
Source: PubMed


To report a patient with severe post-laser in situ keratomileusis (LASIK) epithelial ingrowth and keratolysis treated with flap amputation and phototherapeutic keratectomy (PTK) with adjuvant intraoperative mitomycin C (MMC).
Case report.
A 55-year-old woman was referred to our department due to severe post-LASIK epithelial ingrowth with corneal melting 2 years after primary LASIK. The patient had had two previous attempts for epithelial ingrowth treatment (flap lift and epithelial ingrowth manual removal) that were unsuccessful. Slit lamp biomicroscopy and anterior segment optical coherence tomography showed extensive epithelial ingrowth and keratolysis (thinning of the LASIK flap) while the patient had photophobia and could not tolerate contact lenses. Flap amputation with subsequent PTK (in order to smooth out the corneal irregularities caused by the keratolysis and/or variations in flap thickness) and adjuvant intraoperative MMC application for 2 minutes was performed. There were no intra- or postoperative adverse events seen during the follow-up period. Six months after the procedure, uncorrected visual acuity improved to 20/40 compared with 20/50 preoperatively, while best spectacle-corrected visual acuity improved from 20/40 to 20/32. The topographic astigmatism was decreased from 3.24 diopters (D) to 1.00 D.
Flap amputation with PTK and adjuvant intraoperative MMC is an option for the management of severe post-LASIK epithelial ingrowth with keratolysis.

21 Reads
  • Journal of Cataract and Refractive Surgery 01/2010; 36(1):179-80. DOI:10.1016/j.jcrs.2009.10.023 · 2.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe recent evidence from the literature regarding central toxic keratopathy syndrome (CTK). CTK describes a rare, self-limited, noninflammatory postsurgical condition that presents with central corneal opacity and a significant hyperopic shift. Although its cause remains uncertain, CTK bears a striking clinical resemblance to other more serious conditions and is, therefore, often misdiagnosed and mismanaged. Despite its noninflammatory nature, the overlapping clinical features CTK shares with other inflammatory and infectious processes have led some to treat CTK with steroids. Recent studies discourage the use of steroids in CTK and recommend allowing the condition to resolve on its own. Although CTK resembles other inflammatory conditions that are responsive to steroids, current studies suggest that steroid administration is contraindicated in CTK and can exacerbate preexisting refractive alterations in patients with the condition.
    Current opinion in ophthalmology 07/2010; 21(4):274-9. DOI:10.1097/ICU.0b013e32833a8cb2 · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Experience with mitomycin C (MMC) application during corneal surface ablation procedures such as phototherapeutic keratectomy and photorefractive keratectomy has grown over the last decade. This review will highlight our understanding of the utility, mechanism of action, and safety profile of MMC. MMC, although still off-label treatment for ophthalmic surgical uses, is now widely employed for photorefractive keratectomy corrections of greater than four to six diopters. The last few years have seen the refractive surgery community embrace its use for virtually any corneal surgical procedure that carries an increased risk for haze formation. Experience has shown that MMC is highly effective at preventing haze and is well tolerated, with few reported complications. However, several recent reports have raised new questions about the long-term safety profile of MMC, especially with regard to decreased keratocyte and corneal endothelial cell populations noted months to years after surgery. New findings regarding the penetration of MMC to the endothelium and into the aqueous humor may lead surgeons to reassess appropriate dosing and patient selection when the drug is used for surgery. The use of MMC has revitalized the application of surface ablation procedures such as photorefractive keratectomy or phototherapeutic keratectomy for refractive and therapeutic treatments. Questions remain, however, regarding the long-term safety profile of MMC. A cautious approach to its continued use is advisable.
    Current opinion in ophthalmology 07/2010; 21(4):269-73. DOI:10.1097/ICU.0b013e32833a8c9b · 2.50 Impact Factor
Show more